To have a comprehensive characterization of MSCs from patients affected by PSP involved in this study (Table 1), we first evaluated the expression of many verified and postulated MSC cell surface antigens by flow cytometry on cultured cell lines at passage 2 (P2) in culture. Here, CD53 is linked to supranuclear palsy, progressive, 1.